

7 June 2024

**Graft Polymer (UK) Plc
(the "Company")**

Update on Recent Developments

Graft Polymer (UK) Plc (LSE: GPL), an innovative developer of biopolymer drug delivery systems aimed at enhancing the effectiveness of therapeutics for biopharmaceutical companies, is pleased to provide an overview of recent progress.

Operational Review

On 2 May 2023, the Company announced the initiation of an operational review. The Company is pleased to report that the first phase of this review has concluded. Moving forward, one focus area for the Company will be to seek commercial opportunities for its patented self-nanoemulsifying drug delivery systems (SNEDDS) platform, to enhance the bioavailability, pharmacokinetics, and stability of biopharmaceutical companies' therapeutics.

Currently, the Company is evaluating a shortlist of five entities for potential future commercial collaboration in this space.

Focus on the Healthcare Industry

On 3 May 2024, the Company disclosed the disposal of Graft Polymer d.o.o., allowing us to concentrate our attention and resources on our Graft Bio division. The Directors believe this division holds significant potential due to its intellectual property (IP), licensing agreements, and sales contracts.

Recent Patent Filings

The Company continues to develop its intellectual property portfolio, supporting its focus on the healthcare industry clients and targeting SNEDDS-related commercial collaboration opportunities. Recently, the Company submitted two utility patent applications (provisional) to the United States Patent and Trademark Office (USPTO) for using its SNEDDS platform in drug delivery for substance use disorders and mental health treatment.

On 28 May 2024, the Company filed the first of these applications titled "Composition and Methods for Substance Use Disorders (SUDS) using a Self-Nanoemulsifying Drug Delivery System (SNEDDS)," covering the innovative application of its SNEDDS platform to enhance the bioavailability, pharmacokinetics, and stability of therapeutics used in treating substance use disorders.

On 31 May 2024, the Company filed the second provisional patent titled "Composition and Methods for Mental Health Disorders using a Self-Nanoemulsifying Drug Delivery System (SNEDDS)," covering the innovative application of our SNEDDS platform to enhance the bioavailability, pharmacokinetics, and stability of therapeutics used in treating mental health disorders such as Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD).

Enquiries:

Graft Polymer (UK) Plc:

Anthony Tennyson, CEO and Executive Director: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive Director: yifat@graftpolymer.com

Allenby Capital (Broker):

Phone: +44 (0) 20 3328 5656
Nick Naylor / Liz Kirchner (Corporate Finance)
Guy McDougall (Sales)

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc (LSE: GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDSSEEFMELSEEM